LitAlert ~~ GeneLit.com

    • Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
    • Rodler E, Sharma P, Barlow WE, Gralow JR, Puhalla SL, Anders CK, Goldstein L, Tripathy D, Brown-Glaberman UA, Huynh TT, Szyarto CS, Godwin AK, Pathak HB, Swisher EM, Radke MR, Timms KM, Lew DL, Miao J, Pusztai L, Hayes DF, Hortobagyi GN.
    • Lancet Oncol. 2023 Jan 6:S1470-2045(22)00739-2. doi: 10.1016/S1470-2045(22)00739-2. Epub ahead of print.

    •• Identifier: NCT02595905: Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases. (ClinicalTrials.gov . Accessed 2023 Jan 7.)

    • Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations.
    • Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman MS, Gore JL, Paradysz A, Tilki D, Merseburger AS, Morgan TM, Briganti A, Palapattu GS, Shariat SF.
    • Nat Rev Urol. 2023 Jan 4. doi: 10.1038/s41585-022-00680-4. Epub ahead of print.
    • Review
    • Gene of the month: PALB2.
    • Hamdan O, Nowak KM.
    • J Clin Pathol. 2022 Dec 7:jcp-2022-208461. doi: 10.1136/jcp-2022-208461. Epub ahead of print.
    • Review
    • Comprehensive clinical characterization of patients with BRCA1: c.5017_5019del germline variant.
    • Bang YJ, Kwon WK, Kim JW, Lee JE, Jung BY, Kim M, Kim J, An J, Jung SP, Kim HK, Kim Z, Youn HJ, Ryu JM, Kim SW; Korean Hereditary Breast Cancer Study Group.
    • Ann Surg Treat Res. 2022 Dec;103(6):323-330. doi: 10.4174/astr.2022.103.6.323. Epub 2022 Dec 8.